France Self-Monitoring Blood Glucose Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 532 Million |
| Market Size (2029) | USD 712 Million |
| CAGR (2024 - 2029) | 7.18 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
France Self-Monitoring Blood Glucose Devices Market Analysis
The France Self-Monitoring Blood Glucose Devices Market size is estimated at USD 532 million in 2024, and is expected to reach USD 712 million by 2029, growing at a CAGR of 7.18% during the forecast period (2024-2029).
Blood glucose monitoring increases patients' awareness of glucose values, which supports healthy lifestyle choices. Blood glucose monitoring values help provide feedback and guidance on how to make health behavior changes when needed. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. Appropriate and timely monitoring of blood glucose allows the successful management of out-of-range blood glucose levels, minimizing diabetic-related health complications.
Innovative technologies, such as digital health apps that display and summarize individual blood glucose measurements and incorporate additional relevant data such as insulin doses, meals and snacks, and physical activity, can further support self-management while decreasing disease burden and benefiting overall diabetes care. Integration of blood glucose monitoring with insulin calculators, automated insulin titration software, and remote coaching are further developments that provide patients with poorly controlled diabetes with the additional support needed to improve critical outcomes, thereby enhancing market prospects in the years to come.
France Self-Monitoring Blood Glucose Devices Market Trends
Rising Diabetes Prevalence in France
The diabetes population in France is expected to grow by about 2.9% over the forecast period.
According to the International Diabetes Federation's reports, the prevalence of diabetes in adults in France was approximately 8.6%. Self-monitoring is a commitment that many diabetic patients make to manage their condition. The blood glucose levels help the patients and doctors modify their diet, lifestyle, insulin therapy, and medications to help their blood sugar return to normal. With newer innovations in medical technology, glucometers these days have highly sensitive strips and sensors that can detect every component of blood accurately, close to lab results.
The French health benefit basket plays an important role; diabetes is one of the 30 chronic diseases covered 100% by statutory health insurance pursuant to the ALD scheme (affections de longue durée). For those not covered under ALD, a share of the official health care tariff is paid by the patient and varies depending on the category of goods and care.
The World Health Assembly Resolution recommended the integration of prevention and treatment of diabetes into primary health services, the development of pathways for a substantial increase in access to insulin, the promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it involves the WHO advising the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
The Test Strips Segment holds the highest market share in the current year
The test strip segment holds the highest market share of about 79.5% in the France self-monitoring blood glucose devices market in the current year.
Blood glucose test strips are small, disposable strips and are a key component of blood glucose testing. When blood is placed on the test strip, it reacts with a chemical called glucose oxidase, producing gluconic acid from the glucose in the blood. At the other end of the test strip, the meter transfers a current to the strip. The test strip has electric terminals, which allow the meter to measure the current between the terminals. The current between the terminals changes depending on the level of gluconic acid that has been produced. The blood glucose meter then uses an algorithm to work out the blood glucose level based on the difference in current.
The growth in market share of test strips is expected to be higher than that of glucose meters because of the difference in use-case frequency. The glucometer is a one-time purchase; test strips, on the other hand, are a continuous investment as a test strip needs to be disposed of after one use, causing a recurrent cost impact. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost during the same time frame,
The French healthcare system (Protection Universelle Maladie) is mostly funded by taxes and offers partial health insurance. Usually, employers sign up their employees for social contributions, and a premium is deducted from their salaries through taxes. Whenever someone requires medical attention, up to 70% of their medical costs are already covered by national health insurance, and 100% in the case of someone dealing with a long-term condition like cancer or diabetes.
Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated over the forecast period.
France Self-Monitoring Blood Glucose Devices Industry Overview
The French self-monitoring blood glucose device market is fragmented, with a few significant and other generic players. Manufacturers like Abbott, LifeScan, Roche, Ascensia, etc. occupy a major share.
France Self-Monitoring Blood Glucose Devices Market Leaders
-
Roche Diabetes Care
-
Abbott Diabetes Care
-
Ascensia Diabetes Care
-
LifeScan
-
Arkray
*Disclaimer: Major Players sorted in no particular order
France Self-Monitoring Blood Glucose Devices Market News
- January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.
- January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that would run its own apps. The hand-held Cobas Pulse includes an automated glucose test strip reader as well as a camera and touchscreen for logging other diagnostic results. It's designed to be used with patients of all ages, including neonates and people in intensive care.
France Self-Monitoring Blood Glucose Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Component
- 5.1.1 Glucometer Devices
- 5.1.2 Test Strips
- 5.1.3 Lancets
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes population
- 6.2 Type-2 Diabetes population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Abbott Diabetes Care
- 7.1.2 Roche Diabetes Care
- 7.1.3 LifeScan
- 7.1.4 Ascensia Diabetes Care
- 7.1.5 Bionime Corporation
- 7.1.6 Menarini
- 7.1.7 VivaChek
- 7.1.8 Rossmax International Ltd.
- 7.1.9 Arkray Inc.
- *List Not Exhaustive
- 7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityFrance Self-Monitoring Blood Glucose Devices Industry Segmentation
Self-monitoring of blood glucose is an approach used by diabetic patients to measure their blood sugar level themselves using a glucometer, test strips, and lancets. Based on the readings, patients can adjust or check the effect of their treatment. The French self-monitoring blood glucose device market is segmented by components. The report offers the value (in USD) and volume (in unit) for the above segments.
| Component | Glucometer Devices |
| Test Strips | |
| Lancets |
France Self-Monitoring Blood Glucose Devices Market Research Faqs
How big is the France Self-Monitoring Blood Glucose Devices Market?
The France Self-Monitoring Blood Glucose Devices Market size is expected to reach USD 532 million in 2024 and grow at a CAGR of 7.18% to reach USD 712 million by 2029.
What is the current France Self-Monitoring Blood Glucose Devices Market size?
In 2024, the France Self-Monitoring Blood Glucose Devices Market size is expected to reach USD 532 million.
Who are the key players in France Self-Monitoring Blood Glucose Devices Market?
Roche Diabetes Care, Abbott Diabetes Care, Ascensia Diabetes Care, LifeScan and Arkray are the major companies operating in the France Self-Monitoring Blood Glucose Devices Market.
What years does this France Self-Monitoring Blood Glucose Devices Market cover, and what was the market size in 2023?
In 2023, the France Self-Monitoring Blood Glucose Devices Market size was estimated at USD 493.80 million. The report covers the France Self-Monitoring Blood Glucose Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the France Self-Monitoring Blood Glucose Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
France Self-Monitoring Blood Glucose Devices Industry Report
Statistics for the 2024 France Self-Monitoring Blood Glucose Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. France Self-Monitoring Blood Glucose Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
